An Update on The Economic Impact of Adult Immunisation
By Staff Writer
April 24, 2024
Introduction: The Value of Adult Immunisation in Health Economics
In the face of mounting pressures on global healthcare systems, adult immunisation programmes emerge as a beacon of fiscal responsibility and preventative wisdom. Recent research from the Office of Health Economics (OHE) has illuminated the substantial economic benefits these programs offer across ten diverse countries including Australia, Brazil, Germany, South Africa, Thailand, and the United States. With a return on investment of up to 19 times the initial outlay, the impact of adult immunisation stands as an exemplar of preventive healthcare, contributing to the development of a stronger and more resilient society.
Figure 1. Ten Countries Selected for this Analysis.
The Burden of Vaccine-Preventable Diseases
Vaccine-preventable diseases continue to exert a significant toll on adult populations worldwide. The OHE research underscores the heavy impact of conditions like seasonal influenza, pneumococcal disease, and others on healthcare systems. Adult immunisation programs offer a formidable shield against these diseases, averting severe health outcomes and mortality, especially among the elderly and those with chronic conditions.
Adult Immunisation Economic Impact
The economic modelling conducted by the OHE reveals that adult immunisation programs are not only health-preserving but also cost-saving. By preventing hospitalisations and emergency care, these programs can lead to net cost savings for healthcare systems. For instance, one full vaccination course can yield up to $4637 in net monetary benefits per individual.
Societal and Productivity Gains
Beyond healthcare savings, adult immunisation programs contribute to societal wealth. By preventing disease, they enable individuals to maintain productivity, reducing the economic burden on caregivers and the wider community. This aligns with the broader goals of health and economic equity, particularly benefiting underserved communities.
Figure 2. Percentage of Countries for with Evidence of Positive Impact on Value
Recommendations and Future Directions
The OHE report culminates in key recommendations, advocating for a prevention-first approach and robust funding for adult immunisation. It calls for the expansion of these programs as part of a life-course immunisation strategy, emphasising the need for further research to fill existing evidence gaps and inform policy decisions.
Conclusion
Adult immunisation programs are a cornerstone of preventive healthcare, offering unmatched economic benefits. As healthcare systems confront increasing demands, these programs stand as a testament to the power of prevention, offering a sustainable path forward for societies worldwide
The introduction of the MARIE framework in Japan revolutionizes value-based drug pricing by considering not just costs, but the actual benefits drugs provide to patients and society. This innovative approach significantly adjusts prices based on updated clinical data and allows for more equitable access to therapies.
Curious about how MARIE can reshape drug pricing and pharmaceutical innovation? Dive into the full article for insights!
🧠 What if addressing just a few key lifestyle factors could significantly reduce the risk of stroke, dementia, and depression in older adults?
A recent systematic review has identified 17 **modifiable risk factors**, revealing the interconnected nature of these age-related brain diseases and offering crucial insights for preventive strategies. By focusing on aspects such as blood pressure management, nutrition, and physical activity, we can enhance quality of life for our aging population.
Dive into the article to explore how these findings could shape future healthcare models.
💊 Curious about the future of drug pricing in the U.S.?
The recent executive order aims to tackle escalating prescription drug costs through measures like international reference pricing and enhanced transparency. However, the implications of these policies could be more complex than anticipated, with potential risks to market access and innovation.
Dive into the article for a detailed analysis of how these regulations could shape the pharmaceutical landscape and what it means for healthcare access in the U.S.
#SyenzaNews #pharmaceuticals #healthcarepolicy
When you partner with Syenza, it’s like a Nuclear Fusion.
Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in
health policy, health economics, systems analysis, public finance, business, and project management.
You’ll also feel our high-impact global and local perspectives with cultural intelligence.
